{"product_id":"veriteqcorp-pestle-analysis","title":"VeriTeQ Corp. PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how regulatory shifts, healthcare spending trends, and rapid tech adoption shape VeriTeQ Corp.'s market position—our PESTLE distills risks and opportunities into actionable insights for investors and strategists; buy the full analysis to get a ready-to-use, deep-dive report that powers smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy reform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecent late-2025 federal and state healthcare reforms shifted 28% of Medicare reimbursements toward value-based models, pressuring multi-specialty practices’ margins; for Consensus Health, this could alter $42M of annual revenue tied to fee-for-service contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental healthcare subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal grants and state subsidies for physician-owned practices—totaling roughly $3.5B in 2024 through programs like HRSA and targeted state funds—directly influence VeriTeQ Corp.’s capacity to expand its network by lowering capital barriers for partner practices.\u003c\/p\u003e\n\u003cp\u003eShifts in political support for private healthcare, evidenced by a 12% decline in favorable legislative measures for private entities from 2022–2024, can force VeriTeQ to reassess long-term capital allocation and M\u0026amp;A pacing.\u003c\/p\u003e\n\u003cp\u003eHeightened legislative focus on cost containment has increased regulatory review of management orgs’ admin expenses, with audits of G\u0026amp;A and management fees rising ~18% in 2024, pressuring VeriTeQ to justify and optimize its fee structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policies on medical technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeriTeQ’s shift to services masks continued reliance on RFID and medical hardware, making it vulnerable to trade tensions; US tariffs on electronic components rose to an average 6.1% in 2024, which can raise device input costs for its clinical sites.\u003c\/p\u003e\n\u003cp\u003eImported sensors and chips—often sourced from East Asia—account for roughly 22–28% of BOM costs for cardiac monitoring units, so tariff hikes materially affect margins.\u003c\/p\u003e\n\u003cp\u003ePolitical instability in supplier countries (e.g., Taiwan, Vietnam) risks supply disruptions; a 2023–24 survey found 34% of medtech firms reported lead-time increases \u0026gt;30% due to such risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState licensing and physician autonomy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical debates over mid-level provider scope affect VeriTeQ client staffing: 28 states expanded nurse practitioner autonomy by 2024, reducing reliance on physician FTEs and lowering labor costs for multi-specialty groups by an estimated 6–10%.\u003c\/p\u003e\n\u003cp\u003eState political climates shape autonomy for physician-managed groups like Consensus Health; restrictive states can increase compliance costs—averaging $150k–$300k annually per group.\u003c\/p\u003e\n\u003cp\u003eEfforts like the 2024 Interstate Medical Licensure Compact expansion and proposed federal bills to harmonize licensing could enable VeriTeQ-facilitated geographic expansion, opening markets in 12–15 additional states.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28 states expanded NP autonomy by 2024\u003c\/li\u003e\n\u003cli\u003eLabor cost reduction 6–10% for groups using mid-level autonomy\u003c\/li\u003e\n\u003cli\u003eCompliance costs $150k–$300k\/year in restrictive states\u003c\/li\u003e\n\u003cli\u003eLicensing harmonization could add 12–15 states\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health funding priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe 2024 shift in US federal public health funding increased preventative care allocations by 6.8%, with $12.4B targeted to chronic disease programs—aligning with VeriTeQ’s multi-specialty device portfolio and creating demand for Consensus Health partnerships in community clinics.\u003c\/p\u003e\n\u003cp\u003eHowever, several states adopted austerity cuts in 2025 trimming public health budgets by up to 4.2%, which could constrain reimbursement and slow uptake of specialized services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e+6.8% federal increase in preventative care (2024)\u003c\/li\u003e\n\u003cli\u003e$12.4B for chronic disease programs (2024)\u003c\/li\u003e\n\u003cli\u003eState-level cuts up to 4.2% (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy Shifts Recast VeriTeQ: Margin Pressure, Supply Costs, and 12–15 State Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts since 2024—value-based Medicare (28% shift), $3.5B in practice grants, 6.1% avg tariffs, 28 states NP autonomy—reshape VeriTeQ’s revenue mix, margins, supply costs, staffing models, and expansion prospects; licensing harmonization could add 12–15 states while state cuts (up to 4.2%) and compliance costs ($150k–$300k\/yr) constrain growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare value-based shift\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractice grants\/subsidies (2024)\u003c\/td\u003e\n\u003ctd\u003e$3.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg tariffs on components (2024)\u003c\/td\u003e\n\u003ctd\u003e6.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates with NP autonomy (2024)\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential states added via licensing\u003c\/td\u003e\n\u003ctd\u003e12–15\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState public health cuts (max, 2025)\u003c\/td\u003e\n\u003ctd\u003e4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance cost (restrictive states)\u003c\/td\u003e\n\u003ctd\u003e$150k–$300k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect VeriTeQ Corp. across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and industry-specific subpoints to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE snapshot of VeriTeQ Corp. that’s ready to drop into presentations, visually segmented by category for quick stakeholder alignment and editable for region- or business-specific notes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on clinical operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, medical supply prices rose roughly 8–12% year-over-year, nursing labor costs climbed about 6–9%, and energy expenses increased ~10%, compressing medical group margins by an estimated 150–300 basis points for many practices.\u003c\/p\u003e\n\u003cp\u003eConsensus Health must adopt aggressive cost controls—supply-chain consolidation, staffing optimization, and energy-efficiency investments—to recoup margin erosion amid persistently high inflation.\u003c\/p\u003e\n\u003cp\u003eAbility to pass costs to payers is constrained: median commercial contract rate increases lagged inflation at ~2–3% in 2024–2025, forcing practices to absorb most expense growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe current US federal funds rate at 5.25–5.50% (Fed, Dec 2025) raises VeriTeQ’s borrowing costs, increasing acquisition financing expenses as it pursues new physician practices; higher rates can reduce deal volume by tightening lender terms. Rising rates compress valuations and can slow consolidation in healthcare, evidenced by a Q3 2025 drop in M\u0026amp;A deal value in healthcare by ~12% year-over-year. Investors track VeriTeQ’s debt-to-equity (reported 0.62 at FY2024) versus central bank signals for future rate moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician compensation trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic competition for specialized medical talent has pushed U.S. physician compensation up ~4–6% annually in 2023–2024, with median specialist salaries near $420,000 (MGMA 2024); Consensus Health must match market-driven packages to retain staff without eroding VeriTeQ Corp. margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer healthcare spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpoverall economic health affects patients ability to afford elective procedures and out-of-pocket care with u.s. consumer spending on healthcare rising about of gdp in disposable personal income down real pressuring demand for nonessential services veriteq revenue sensitivity local levels.\u003e\n\u003cpin recessions patient volumes for multi-specialty groups fall and bls data show elective procedure dropped in similar declines recur during downturns veriteq service utilization recurring revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHealthcare spend ~17.9% of GDP (2023)\u003c\/li\u003e\n\u003cli\u003eDisposable personal income real decline ~0.1% (2024)\u003c\/li\u003e\n\u003cli\u003eElective procedure volume drops ~8–12% in downturns\u003c\/li\u003e\n\u003cli\u003eRevenue sensitive to regional disposable income\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pin\u003e\u003c\/poverall\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance reimbursement rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNegotiations with private insurers and updated 2025 Medicare\/Medicaid fee schedules—Medicare increased certain device reimbursement by ~2.5% in CY2025—are primary drivers of VeriTeQ’s revenue, impacting per-procedure margins.\u003c\/p\u003e\n\u003cp\u003eThe shift to risk-sharing models forces VeriTeQ to deliver measurable outcome improvements; under value-based contracts, readmission reductions of 5–10% can materially affect payments.\u003c\/p\u003e\n\u003cp\u003ePayer consolidation (top five insurers controlling ~60% of US market in 2024) compresses bargaining power, risking lower reimbursement rates and higher contract pressure on VeriTeQ’s pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare device reimbursement +2.5% CY2025\u003c\/li\u003e\n\u003cli\u003eValue-based clause: 5–10% readmission impact\u003c\/li\u003e\n\u003cli\u003eTop 5 payers ≈60% market share (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, high rates and payer consolidation squeeze margins—value-based efficiency vital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersistent inflation (medical supplies +8–12% YoY, energy ~10% in 2025) and Fed rates 5.25–5.50% (Dec 2025) have squeezed margins ~150–300 bps and raised borrowing costs, limiting M\u0026amp;A and increasing acquisition financing expenses.\u003c\/p\u003e\n\u003cp\u003eWage pressure (physician pay +4–6%; median specialist ~$420k) and payer rate increases lagging inflation (~2–3%) force cost absorption, lowering per-procedure margins and sensitivity to local disposable income declines.\u003c\/p\u003e\n\u003cp\u003ePayor consolidation (top 5 ≈60% market share) plus Medicare device +2.5% CY2025 and shift to value-based contracts (5–10% readmission impact) heighten revenue risk and require outcomes-based efficiency to protect margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical supply inflation (2025)\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (Dec 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician pay growth\u003c\/td\u003e\n\u003ctd\u003e+4–6% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 5 payers market share (2024)\u003c\/td\u003e\n\u003ctd\u003e≈60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eVeriTeQ Corp. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact VeriTeQ Corp. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751341863289,"sku":"veriteqcorp-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/veriteqcorp-pestle-analysis.png?v=1772230419","url":"https:\/\/growthsharematrix.com\/products\/veriteqcorp-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}